Skip to main content
SpringerLink
Log in

Onkologika

  • Chapter
  • First Online:
Arzneiverordnungs-Report 2020

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Almasri J, Alkhateeb HB, Firwana B, Sonbol MB, Damlaj M, Wang Z, Murad MH, Al-Kali A (2018) A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome. Syst Rev 7:144. https://doi.org/10.1186/s13643-018-0805-7

    Article  PubMed  PubMed Central  Google Scholar 

  • Alsdorf W, Seidel C, Bokemeyer C, Oing C (2019) Current pharmacotherapy for testicular germ cell cancer. Expert Opin Pharmacother 20:837–850

    CAS  PubMed  Google Scholar 

  • von Amsberg G, Merseburger AS (2020) Therapie des metastasierten kastrationsresistenten Prostatakarzinoms. Urologe 59:673–679

    Google Scholar 

  • Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS (2016) Prostate cancer. Lancet 387:70–82

    PubMed  Google Scholar 

  • Baraibar I, Melero I, Ponz-Sarvise M, Castanon E (2019) Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer. Drug Saf 42:281–294

    CAS  PubMed  Google Scholar 

  • Baraniskin A, Buchberger B, Pox C, Graeven U, Holch JW, Schmiegel W, Heinemann V (2019) Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Eur J Cancer 106:37–44

    CAS  PubMed  Google Scholar 

  • Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B, PREVAIL Investigators (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433

    PubMed  PubMed Central  Google Scholar 

  • De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

    PubMed  Google Scholar 

  • Bundesministerium für Gesundheit (2014) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V), Ruxolitinib vom 6. November 2014, veröffentlicht Montag, 15. Dezember 2014, BAnz AT 15. Dez. 2014 B4

    Google Scholar 

  • Bundesministerium für Gesundheit (2015) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Eribulin (neues Anwendungsgebiet) vom 22. Januar 2015, veröffentlicht am Montag, 16. Februar 2015 BAnz AT 16. Febr. 2015 B3 Seite 1 von 9

    Google Scholar 

  • Bundesministerium für Gesundheit (2016a) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Elotuzumab vom 1. Dezember veröffentlicht am Mittwoch, 28. Dezember 2016 BAnz AT 28. Dez. 2016 B2 Seite 1 von 6

    Google Scholar 

  • Bundesministerium für Gesundheit (2018a) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Carfilzomib (Neubewertung eines Orphan Drugs nach on Arzneimitteln mit neuen Wirkstoffen nach) Vom 15. Februar 2018, Veröffentlicht am Freitag, 9. März 2018 BAnz AT 9. März 2018 B2 Seite 1 von 10

    Google Scholar 

  • Bundesministerium fur Gesundheit (2018c) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses uber eine Anderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlusse uber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Funften Buches Sozialgesetzbuch (SGB V) Ribociclib vom 16. Marz 2018 veroffentlicht am Donnerstag, 12. April 2018 BAnz AT 12. Apr. 2018 B1 Seite 1 von 6

    Google Scholar 

  • Bundesministerium für Gesundheit (2019a) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Palbociclib (Brustkrebs; in Kombination mit Fulvestrant nach endokriner Therapie; Neubewertung nach Fristablauf) Vom 22. März 2019 Veröffentlicht am Dienstag, 16. April 2019 BAnz AT 16. Apr. 2019 B3

    Google Scholar 

  • Bundesministerium für Gesundheit (2019b) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Ribociclib (neues Anwendungsgebiet: Brustkrebs, in Kombination mit Fulvestrant) vom 4. Juli 2019, BAnz AT 26. Aug. 2019 B7

    Google Scholar 

  • Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P, RESONATE Investigators (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213–223

    PubMed  PubMed Central  Google Scholar 

  • Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C, Herceptin Adjuvant (HERA) Trial Study Team (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389:1195–1205

    CAS  PubMed  PubMed Central  Google Scholar 

  • Capal JK, Franz DN (2016) Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy. Neuropsychiatr Dis Treat 12:2165–2172

    CAS  PubMed  PubMed Central  Google Scholar 

  • Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, van Hasselt JGC (2019) Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet 58:835–857

    PubMed  PubMed Central  Google Scholar 

  • Cervantes F (2014) How I treat myelofibrosis. Blood 124:2635–2642

    CAS  PubMed  Google Scholar 

  • Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 359:613–626

    CAS  PubMed  Google Scholar 

  • Cheson BD, Rummel MJ (2009) Bendamustine: rebirth of an old drug. J Clin Oncol 27:1492–1501

    CAS  PubMed  Google Scholar 

  • Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X (2015) New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 36:587–595

    CAS  PubMed  PubMed Central  Google Scholar 

  • Choueiri TK, Motzer RJ (2017) Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 376:354–366

    CAS  PubMed  Google Scholar 

  • Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DY, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ, METEOR investigators (2016) Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17:917–927

    CAS  PubMed  Google Scholar 

  • Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174

    CAS  PubMed  Google Scholar 

  • Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    CAS  PubMed  Google Scholar 

  • Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med 372:793–795

    CAS  PubMed  PubMed Central  Google Scholar 

  • Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C, EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) investigators (2011) Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9):914–923

    CAS  PubMed  Google Scholar 

  • Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM et al (2018) Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 132:393–404

    CAS  PubMed  PubMed Central  Google Scholar 

  • Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L (2017) Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15:1520–1541

    CAS  PubMed  Google Scholar 

  • Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al (2004) A randomised comparison of cetuximab monotherapy and cetuximab plus Irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    CAS  PubMed  Google Scholar 

  • van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664

    PubMed  Google Scholar 

  • van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019

    PubMed  Google Scholar 

  • van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422

    PubMed  Google Scholar 

  • Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC/LATTE investigators (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141

    CAS  PubMed  Google Scholar 

  • Van Dalen EC, van der Pal HJ, Kremer LC (2016) Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005008.pub4

    Article  PubMed  PubMed Central  Google Scholar 

  • Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ, ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381:121–131

    CAS  PubMed  Google Scholar 

  • Der Arzneimittelbrief (2018) Multiples Myelom: Das Zeitalter der Immuntherapie hat begonnen. AMB 52:9

    Google Scholar 

  • Der Arzneimittelbrief (2019) Chronische lymphatische Leukämie: Erstlinientherapie mit neuen Wirkstoffen. AMB 53:49

    Google Scholar 

  • Der Arzneimittelbrief (2020) Ibrutinib: neue Erkenntnisse zu kardiovaskulräen Nebenwirkungen unter „Real-World“-Bedingungen. AMB 54:1

    Google Scholar 

  • Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) (2019) Positionspapier Qualitätsgesicherte Molekulardiagnostik in der Onkologie. https://www.dgho.de/publikationen/stellungnahmen/gute-aerztliche-praxis/molekulare-diagnostik

  • Deutsche Krebsgesellschaft e.V., Deutschen Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (2018) Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms Kurzversion 4.1 – September 2018, AWMF-Registernummer: 032-045OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/ (Federführende Fachgesellschaften Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG), Deutsche Krebsgesellschaft (DKG))

  • Deutsche Krebsgesellschaft e.V., Deutschen Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (2019) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Kurzversion 5.1 – Mai 2019, AWMF-Register-Nummer 043/022OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ (Federführende Fachgesellschaft Deutsche Gesellschaft für Urologie e. V. (DGU))

  • DeVita VT, Rosenberg SA (2012) Two hundred years of cancer research. N Engl J Med 366:2207–2214

    CAS  PubMed  PubMed Central  Google Scholar 

  • Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P (2017a) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18:1327–1337

    CAS  PubMed  Google Scholar 

  • Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P (2017b) Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol 178:896–905

    CAS  PubMed  PubMed Central  Google Scholar 

  • Dobbelstein M, Moll U (2014) Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov 13:179–196

    CAS  PubMed  Google Scholar 

  • van de Donk NWCJ, Moreau P, Plesner T, Palumbo A, Gay F, Laubach JP, Malavasi F, Avet-Loiseau H, Mareos M-V, Sonneveld P, Lokhorst HM, Richardson PG (2016) Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 127:681–695

    PubMed  Google Scholar 

  • Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705

    CAS  PubMed  Google Scholar 

  • Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034

    CAS  PubMed  Google Scholar 

  • Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, Moreno C, Robak T, Stilgenbauer S, Montserrat E, European Research Initiaitve on CLL (ERIC) and the european Society for Blood and Marrow Transplantation (EBMT) (2018) High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood 132(9):892–902

    CAS  PubMed  Google Scholar 

  • Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519–527

    CAS  PubMed  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Google Scholar 

  • Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiówka M, Hewson N, Rukazenkov Y, Robertson JF (2015) Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol 33:3781–3787

    CAS  PubMed  PubMed Central  Google Scholar 

  • EMA: Committtee for Medicinal Products for Human Use (CHMP) (2015) Summary of opinion (post-authorisation). https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-abraxane_en.pdf

  • Ernst E, Schmidt K, Steuer-Vogt MK (2003) Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 107:262–267

    CAS  PubMed  Google Scholar 

  • Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, Guerci-Bresler A, Legros L, Varet B, Gardembas M, Dubruille V, Tulliez M, Noel MP, Ianotto JC, Villemagne B, Carré M, Guilhot F, Rousselot P, Mahon FX (2017) Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 35:298–305

    PubMed  Google Scholar 

  • Falzone L, Salomone S, Libra M (2018) Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol 9(1300):2018. https://doi.org/10.3389/fphar.2018.01300

    Article  CAS  Google Scholar 

  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR, International Vidaza High-Risk MDS Survival Study Group (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232

    CAS  PubMed  PubMed Central  Google Scholar 

  • Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375:1925–1936

    CAS  PubMed  Google Scholar 

  • Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN, LATITUDE Investigators (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352–360

    CAS  PubMed  Google Scholar 

  • Food and Drug Administration (2011) FDA Commissioner removes breast cancer indication from avastin label. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279485.htm

  • Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, Hui R, Hochmair MJ, Clingan P, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Garon EB, Novello S, Rubio-Viqueira B, Boyer M, Kurata T, Gray JE, Yang J, Bas T, Pietanza MC, Garassino MC (2020) Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum 2020 for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 38(14):1505–1517

    PubMed  Google Scholar 

  • Gemeinsamer Bundesausschuss (2020) Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V Niraparib (Neubewertung eines Orphan-Drugs nach Überschreitung der 50 Mio. Euro Grenze (Ovarialkarzinom, Eileiterkarzinom oder primäre Peritonealkarzinose; Erhaltungstherapie nach Zweitlinientherapie)) vom 2. April 2020. Internet: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/500/#beschluesse

  • Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S (2016) Diagnostik und Therapie des Multiplen Myeloms. Dtsch Arztebl 113:470–476

    Google Scholar 

  • Gharwan H, Groninger H (2016) Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 13:209–227

    CAS  PubMed  Google Scholar 

  • Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375:209–219

    CAS  PubMed  PubMed Central  Google Scholar 

  • Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA (2016) First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010383.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  • Gregory RK, Smith IE (2000) Vinorelbine – a clinical review. Br J Cancer 82:1907–1913

    CAS  PubMed  PubMed Central  Google Scholar 

  • Grgic T, Mis L, Hammond JM (2011) Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma. Ann Pharmacother 45:78–83

    CAS  PubMed  Google Scholar 

  • Guglielmelli P, Vannucchi AM (2020) Current management strategies for polycythemia vera and essential thrombocythemia. Blood Rev. https://doi.org/10.1016/j.blre.2020.100714

    Article  PubMed  Google Scholar 

  • Hall ME, Huelster HL, Luckenbaugh AN, Laviana AA, Keegan KA, Klaassen Z, Moses KA, Wallis CJD (2020) Metastatic hormone-sensitive prostate cancer: Current perspective on the evolving therapeutic landscape. Onco Targets Ther 13:3571–3581

    PubMed  PubMed Central  Google Scholar 

  • Hanahan D (2014) Rethinking the war on cancer. Lancet 383:558–563

    PubMed  Google Scholar 

  • Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674

    CAS  PubMed  Google Scholar 

  • Hansel TT, Kropshofer H, Singer T, Mitcehll JA, George AJT (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9:325–338

    CAS  PubMed  Google Scholar 

  • Harousseau J-L, Attal M (2017) How I treat first relapse of myeloma. Blood 130:963–973

    CAS  PubMed  Google Scholar 

  • Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787–798

    CAS  PubMed  Google Scholar 

  • Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR, United Kingdom Medical Research Council Primary Thrombocythemia 1 Study (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33–45

    CAS  PubMed  Google Scholar 

  • Haslam A, Prasad V (2019) Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. Jama Nework Open 2:e192535

    Google Scholar 

  • Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365

    CAS  PubMed  Google Scholar 

  • He P-F, Zhou J-D, Yao D-M, Ma J-C, Wen X-M, Zhang Z-H, Lian X-Y, Xu Z-J, Qian J, Lin J (2017) Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Oncotarget 8:41498–41507

    PubMed  PubMed Central  Google Scholar 

  • Heigener DF, Kerr KM, Laing GM, Mok TSK, Moiseyenko FV, Reck M (2019) Redefining treatment paradigms in first-line advanced non-small-cell lung cancer. Clin Cancer Res 25:4881–4887

    CAS  PubMed  Google Scholar 

  • Ho GY, Woodward N, Coward JI (2016) Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol 102:37–46

    PubMed  Google Scholar 

  • Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O’Brien SG, Druker BJ, IRIS Investigators (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376:917–927

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R (2020a) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966–984

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hochhaus A, Breccia M, Saglio G, García-Gutiérrez V, Réa D, Janssen J, Apperley J (2020b) Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia 34(6):1495–1502

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hofheinz RD, Beyer U, Al-Batran SE, Hartmann JT (2008) Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives. Onkologie 31:271–281

    CAS  PubMed  Google Scholar 

  • Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andre F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O’Shaughnessy J (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738–1748

    CAS  PubMed  Google Scholar 

  • Howell A, Robertson JFR, Quaresma AJ, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002) Fulvestrant (ICI 182,780) is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing progressing after prior endocrine treatment. J Clin Oncol 20:3396–3403

    CAS  PubMed  Google Scholar 

  • Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22:1605–1613

    CAS  PubMed  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    CAS  PubMed  Google Scholar 

  • Iovino L, Shadman M (2020) Novel therapies in chronic lymphocytic leukemia: a rapidly changing landscape. Curr Treat Options Oncol 21:24. https://doi.org/10.1007/s11864-020-0715-5

    Article  PubMed  Google Scholar 

  • IQVIA Institute for Human Data Science (2019) The changing landscape of research and development. Innovation, drivers of change, and evolution of clinical trialproductivity. https://www.iqvia.com/insights/the-iqvia-institute/reports/the-changing-landscape-of-research-and-development

  • Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists’ Group (2010) Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide early prostate cancer programme at a median follow-up of 9.7 years. BJU Int 105:1074–1081

    CAS  PubMed  Google Scholar 

  • Jabbour E, Kantarjian H (2018) Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 93:442–459

    PubMed  Google Scholar 

  • James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O’Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR, STAMPEDE Investigators (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338–351

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet 384:1376–1388

    PubMed  Google Scholar 

  • Jerusalem G, Rorive A, Collignon J (2015) Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer. Future Oncol 11:1775–1789

    CAS  PubMed  Google Scholar 

  • Joppi R, Gerardi C, Bertele V, Garattini S (2016) Letting post-marketing bridge the evidence gap: the case of orphan drugs. BMJ 353:i2978. https://doi.org/10.1136/bmj.i2978

    Article  PubMed  Google Scholar 

  • June CH, Sadelain M (2018) Chimeric antigen receptor therapy. N Eng J Med 379:64–72

    CAS  Google Scholar 

  • Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W (2016) Bladder cancer. Lancet 388:2796–2810

    PubMed  Google Scholar 

  • Kamisawa T, Wood LD, Itoi T, Takaori K (2016) Pancreatic cancer. Lancet 388:73–85

    CAS  PubMed  Google Scholar 

  • Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376:836–847

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S (2015) Immuntherapie von Tumoren. Aktivierte T-Zellen als neues Behandlungsprinzip. Dtsch Arztebl 112:809–815

    Google Scholar 

  • Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC (2017) Multiple myeloma. Nat Rev Dis Primers 20(3):17046–12017. https://doi.org/10.1038/nrdp.2017.46

    Article  Google Scholar 

  • Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ (2014) Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009266.pub2

    Article  PubMed  Google Scholar 

  • Kundranda MN, Niu J (2015) Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther 9:3767–3777

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lao J, Madani J, Puértolas T, Alvarez M, Hernández A, Pazo-Cid R, Artal A, Torres AA (2013) Liposomal doxorubicin in the treatment of breast cancer patients: a review. Drug Deliv 2013:456409

    Google Scholar 

  • Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O’Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG (2016) Management of relapsed multiple myeloma: recommendations of the international myeloma working group. Leukemia 30:1005–1017

    CAS  PubMed  Google Scholar 

  • Lecavalier-Barsoum M, Quon H, Abdulkarim B (2014) Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007104.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  • Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Eng J Med 366:1382–1392

    CAS  Google Scholar 

  • Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852–861

    CAS  PubMed  Google Scholar 

  • Lee CI, Goodwin A, Wilcken N (2017) Fulvestrant for hormone-sensitive metastatic breast cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011093.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  • Leitlinienprogramm Onkologie, Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF: S3-Leitlinie zur Diagnostik, Therapie und Nachsorge für Patienten mit einer chronischen lymphatischen Leukämie: http://www.leitlinienprogramm-onkologie.de/leitlinien/chronische-lymphatische-leukaemie-cll/ (letzter Zugriff: 5. Juni 2020). AWMF-Register Nr. 018/032OL.

  • Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M (2014) Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 106:djt337

    PubMed  Google Scholar 

  • Lyman GH, Moses HL (2016) Biomarker tests for molecularly targeted therapies – the key to unlocking precision medicine. N Engl J Med 375:4–6

    PubMed  Google Scholar 

  • Ma YY, Zhao M, Liu Y, Zhao DF, Wang LX, Chen XP, Li L (2019) Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis. Hematology 24:507–515

    PubMed  Google Scholar 

  • Macedo LT, da Costa Lima AB, Sasse AD (2012) Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer 12:89. https://doi.org/10.1186/1471-2407-12-89

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mailankody S, Prasad V (2015) Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol 1:539–540

    PubMed  Google Scholar 

  • Manson G, Norwood J, Marabelle A, Kohrt H, Houot R (2016) Biomarkers associated with checkpoint inhibitors. Ann Oncol 27:1199–1206

    CAS  PubMed  Google Scholar 

  • Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377:1331–1344

    CAS  PubMed  Google Scholar 

  • Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y (2018) Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol 11:8

    PubMed  PubMed Central  Google Scholar 

  • Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J (2020) Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395:132–141

    CAS  PubMed  Google Scholar 

  • Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A, RECOURSE Study Group (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909–1919

    PubMed  Google Scholar 

  • McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M (2017) Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 35:3279–3289

    CAS  PubMed  PubMed Central  Google Scholar 

  • McKeage K, Wagstaff AJ (2007) Sorafenib: in advanced renal cancer. Drugs 67:475–483

    CAS  PubMed  Google Scholar 

  • Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476–487

    CAS  PubMed  Google Scholar 

  • San Miguel J (2015) Introduction to a series of reviews on multiple myeloma. Blood 125:3039–3040

    Google Scholar 

  • San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14:1055–1066

    CAS  PubMed  Google Scholar 

  • Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dorum A, Tinker AV, du Bois A, Gonzalez-Martin A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA, Investigators E-ON (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154–2164

    CAS  PubMed  Google Scholar 

  • Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6:229–239

    CAS  PubMed  Google Scholar 

  • Moreau P (2017) How I treat myeloma with new agents. Blood 130:1507–1513

    CAS  PubMed  Google Scholar 

  • Moreau P, Rajkumar SV (2016) Multiple myeloma – translation of trial results into reality. Lancet 388:111–113

    PubMed  Google Scholar 

  • Mori K, Miura N, Mostafaei H, Quhal F, Motlagh SR, Pradere B, Kimura S, Kimura T, Egawa S, Briganti A, Karakiewicz PI, Shariat SF (2020) Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-020-0222-6

    Article  PubMed  Google Scholar 

  • Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722–731

    CAS  PubMed  Google Scholar 

  • Mullard A (2020) 2019 FDA drug approvals. Nature Rev Drug Discov 19:79–84

    CAS  Google Scholar 

  • Nagasawa DT, Chow F, Yew A, Kim W, Cremer N, Yang I (2012) Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am 23:307–322

    PubMed  Google Scholar 

  • National Institute for Health and Care Excellence (2019) Prostate cancer: diagnosis and management. NICE guideline (NG131). Published: 9 May 2019. http://www.nice.org.uk/guidance/ng131

  • Navarra P, Preziosi P (1999) Hydroxyurea: new insights on an old drug. Crit Rev Oncol Hematol 29:249–255

    CAS  PubMed  Google Scholar 

  • O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004

    PubMed  Google Scholar 

  • Onkopedia Leitlinien (2018) Essentielle (oder primäre) Thrombozythämie (ET). https://www.onkopedia.com/de/onkopedia/guidelines

  • Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A (2002) A double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant with anastrozole in post-menopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a north American trial. J Clin Oncol 20:3386–3395

    CAS  PubMed  Google Scholar 

  • Palumbo A, Mina R (2013) Management of older adults with multiple myeloma. Blood Rev 27:133–142

    CAS  PubMed  Google Scholar 

  • Pardanani A, Tefferi A (2018) How I treat myelofibrosis after failure of JAK inhibitors. Blood 132:492–500

    CAS  PubMed  Google Scholar 

  • Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32:3744–3752

    CAS  PubMed  PubMed Central  Google Scholar 

  • Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829–838

    CAS  PubMed  Google Scholar 

  • Peters S, Kerr KM, Stahel R (2018) PD-1 blockade in advanced NSCLC: a focus on pembrolizumab. Cancer Treat Rev 62:39–49

    CAS  PubMed  Google Scholar 

  • Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, Guilhot F, Heibl S, Hehlmann R, Faber E, Turkina A, Ossenkoppele G, Höglund M, Zaritskey A, Griskevicius L, Olsson-Strömberg U, Everaus H, Koskenvesa P, Labar B, Sacha T, Zackova D, Cervantes F, Colita A, Zupan I, Bogdanovic A, Castagnetti F, Guilhot J, Hasford J, Hochhaus A, Hoffmann VS (2020) The EUTOS long-term survival (ELTS) score is superior to the Sokal score for prediting survival in chronic myeloid leukemia. Leukemia. https://doi.org/10.1038/s41375-020-0931-9

    Article  PubMed  PubMed Central  Google Scholar 

  • Pizzolato JF, Saltz LB (2003) The camptothecins. Lancet 361:2235–2242

    CAS  PubMed  Google Scholar 

  • Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S, ESMO Guidelines Committee (2019) Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv192–iv237

    Google Scholar 

  • Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Eng J Med 378:158–168

    CAS  Google Scholar 

  • Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS, Society for Immunotherapy of Cancer Toxicity Management Working Group (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(29162153):95. https://doi.org/10.1186/s40425-017-0300-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rajkumar SV (2020) Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95:548–567

    CAS  PubMed  Google Scholar 

  • Rajkumar SV, Harousseau JC (2016) Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood 128:2757–2764

    CAS  PubMed  PubMed Central  Google Scholar 

  • Rajkumar SV, Kyle RA (2016) Progress in myeloma – a monoclonal breakthrough. N Engl J Med 375:1390–1392

    PubMed  Google Scholar 

  • Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC, FLAURA Investigators (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382:41–50

    CAS  PubMed  Google Scholar 

  • Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, Hochhaus A, Lüftner D, Müller OJ, Neudorf U, Pfister R, von Haehling S, Lehmann LH, Bauersachs J; Committee for Clinical Cardiovascular Medicine of the German Cardiac Society (2020) Onco-Cardiology: Consensus paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol. 2020 May 13. https://doi.org/10.1007/s00392-020-01636-7. Online ahead of print

  • Raza S, Safyan RA, Rosenbaum E, Bowman AS, Lentzsch S (2017) Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. Ther Adv Hematol 8:55–70

    CAS  PubMed  Google Scholar 

  • Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, Novello S, LUME-Lung 1 Study Group (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomized controlled trial. Lancet Oncol 15:143–155

    CAS  PubMed  Google Scholar 

  • Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, OAK Study Group (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265

    PubMed  Google Scholar 

  • Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Her A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015a) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330

    CAS  PubMed  Google Scholar 

  • Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, KEYNOTE-006 investigators (2015b) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532

    CAS  PubMed  Google Scholar 

  • Roberts K, Culleton V, Lwin Z, O’Byrne K, Hughes BG (2017) Immune checkpoint inhibitors: navigating a new paradigm of treatment toxicities. Asia Pac J Clin Oncol 13:277–288

    PubMed  Google Scholar 

  • Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, Lindemann J, Ellis MJ (2009) Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 27:4530–4535

    CAS  PubMed  Google Scholar 

  • Rosario DJ, Davey P, Green J, Greene D, Turner B, Payne H, Kirby M (2016) The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. World J Urol 34:1601–1609

    CAS  PubMed  PubMed Central  Google Scholar 

  • Rugo HS (2019) Achieving improved survival outcomes in advanced breast cancer. N Engl J Med 381:371–372

    PubMed  Google Scholar 

  • Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, COU-AA-302 Investigators (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152–160

    CAS  PubMed  Google Scholar 

  • Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, Roden DM, Moslehi JJ (2019) Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol 74(13):1667–1678

    CAS  PubMed  Google Scholar 

  • Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019

    CAS  PubMed  Google Scholar 

  • Sartor O, de Bono JS (2018) Metastatic prostate cancer. N Eng J Med 378:645–657

    CAS  Google Scholar 

  • Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, AFFIRM Investigators (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197

    CAS  PubMed  Google Scholar 

  • Schilsky RL (2018) A new IDEA in adjuvant chemotherapy for colon cancer. N Engl J Med 378:1242–1244

    PubMed  Google Scholar 

  • Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J (2014) Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol 36:503–517

    CAS  PubMed  PubMed Central  Google Scholar 

  • Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278–287

    CAS  PubMed  Google Scholar 

  • Shankland KR, Armitage JO, Hancock BW (2012) Non-Hodgkin lymphoma. Lancet 380:848–857

    PubMed  Google Scholar 

  • Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK (2018) Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 36:728–734

    CAS  PubMed  Google Scholar 

  • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    CAS  PubMed  Google Scholar 

  • Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G (2020) Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 382:514–524

    Google Scholar 

  • Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update (2015). J Clin Oncol 33:3199–3212

    CAS  PubMed  Google Scholar 

  • Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30:2055–2062

    CAS  PubMed  Google Scholar 

  • Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O’Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D (2016) Metastatic pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol 34:2784–2796

    PubMed  PubMed Central  Google Scholar 

  • Spivak JL (2017) Myeloproliferative neoplams. N Engl J Med 376:2168–2181

    CAS  PubMed  Google Scholar 

  • Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP (2019) Chemotherapy for pancreatic cancer. Presse Med 48:e159–e174

    PubMed  Google Scholar 

  • Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, Hehlmann R, Clark RE (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30:1648–1671

    CAS  PubMed  PubMed Central  Google Scholar 

  • Stilgenbauer S, Hallek M (2013) Chronische lymphatische Leukämie. Therapie und genetisches Risikoprofil. Internist 54:164–170

    CAS  PubMed  Google Scholar 

  • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    CAS  PubMed  Google Scholar 

  • Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461–471

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tang J, Shalabi A, Hubbard-Lucey VM (2018) Comprehensive analysis of the clinical immune-oncology landscape. Ann Oncol 29:84–91

    CAS  PubMed  Google Scholar 

  • Tannock IF, Hickman JA (2016) Limits to personalized medicine. N Engl J Med 375:1289–1294

    PubMed  Google Scholar 

  • Tefferi A, Pardanani A (2019) Essential thrombocythemia. N Engl J Med 381:2135–2144

    PubMed  Google Scholar 

  • Thomas A, Teicher BA, Hassan RR (2016) Antibody-drug conjugates for cancer thwerapy. Lancet Oncol 17:e254–262

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tomasini P, Barlesi F, Mascaux C, Greillier L (2016) Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes. Ther Adv Med Oncol 8:198–208

    CAS  PubMed  PubMed Central  Google Scholar 

  • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Drilon A, Wolchok JD, Carvajal RD, McHenry MB, Hosein F, Harbison CT, Grosso JF, Sznol M (2019) Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol 5:1411–1420

    PubMed Central  PubMed  Google Scholar 

  • Von Tresckow J, Eichhorst B, Bahlo J, Hallek M (2019) Behandlung der chronischen lymphatischen Leukämie. Dtsch Arztebl 116:41–46

    Google Scholar 

  • Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379:1926–1936

    CAS  PubMed  Google Scholar 

  • Valdes M, Nicholas G, Goss GD, Wheatley-Price P (2016) Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy. Curr Oncol 23:386–390

    CAS  PubMed  PubMed Central  Google Scholar 

  • Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372:426–435

    PubMed  PubMed Central  Google Scholar 

  • Varga C, Maglio M, Ghobrial IM, Richardson PG (2018) Current use of monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 181:447–459

    CAS  PubMed  Google Scholar 

  • Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, EMILIA Study Group (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791

    CAS  PubMed  PubMed Central  Google Scholar 

  • Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799–807

    CAS  PubMed  PubMed Central  Google Scholar 

  • Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, Langmuir P, Dong T, Gopalakrishna P, Gupta V (2017) Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 10:156. https://doi.org/10.1186/s13045-017-0527-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339:1546–1558

    CAS  PubMed  PubMed Central  Google Scholar 

  • Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T et al (2020) Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol 21:664–670

    CAS  PubMed  Google Scholar 

  • Wagner AD, Thomssen C, Haerting J, Unverzagt S (2012) Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008941.pub2

    Article  PubMed  Google Scholar 

  • Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721–1728

    PubMed  PubMed Central  Google Scholar 

  • Weeraratna AT (2012) RAF around the edges – the paradox of BRAF inhibitors. N Engl J Med 366:271–273

    CAS  PubMed  Google Scholar 

  • Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715

    CAS  PubMed  Google Scholar 

  • Wierda WG, Byrd JC, Abramson JS et al (2020) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology: https://jnccn.org/view/journals/jnccn/18/2/article-p185.xml. J Natl Compr Canc Netw 18:185–217

    PubMed  Google Scholar 

  • Wilson RAM, Evans TRJ, Fraser AR, Nibbs RJB (2017) Immune checkpoint inhibitors: new strategies to checkmate cancer. Clin Exp Immunol 191:133–148

    PubMed  PubMed Central  Google Scholar 

  • Wu Y, Chen W, Xu ZP, Gu W (2019) PD-L1 distribution and perspective for cancer immunotherapy – Blockade, knockdown, or inhibition. Front Immunol 10:2022. https://doi.org/10.3389/fimmu.2019.02022

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yamaguchi N, Fujii T, Aoi S, Kozuch PS, Hortobagyi GN, Blum RH (2015) Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. Eur J Cancer 51:2314–2320

    CAS  PubMed  Google Scholar 

  • Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O’Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16:141–151

    CAS  PubMed  Google Scholar 

  • Zimmermann S, Peters S (2019) Appraising the tail of the survival curve in the era of PD-1/PD-L1 checkpoint blockade. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.2186

    Article  PubMed  PubMed Central  Google Scholar 

  • Zolot RS, Basu S, Million RP (2013) Antibody-drug conjugates. Nat Rev Drug Discov 12:259–260

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ), Herbert-Lewin-Platz 1, 10623, Berlin, Deutschland

    Prof. Dr. med. Wolf-Dieter Ludwig

  2. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Deutschland

    Prof. em. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Wolf-Dieter Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. em. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolf-Dieter Ludwig .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Ulrich Schwabe

  2. Arzneimittelkommission der deutschen Ärzteschaft, Berlin, Berlin, Germany

    Wolf-Dieter Ludwig

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Der/die Herausgeber bzw. der/die Autor(en), exklusiv lizenziert durch Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ludwig, WD., Schwabe, U. (2020). Onkologika. In: Schwabe, U., Ludwig, WD. (eds) Arzneiverordnungs-Report 2020. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62168-4_34

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62168-4_34

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62167-7

  • Online ISBN: 978-3-662-62168-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation